drugset / Trial / NCT06238752
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
NaSingle-groupOpen-labelTreatment
Summary
In this clinical study, investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent (apatinib), ICI (tislelizumab), and chemotherapy (capecitabine+ Oxaliplatin, XELOX) as first-line treatment for HER2-negative, advanced G/GEJ cancer patients with signet ring cell carcinoma or peritoneal metastasis.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-03-01
- Completion
- 2024-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |